ePrints

Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: Results from a UK Dermatology Clinical Trials Network survey of dermatologists

Lookup NU author(s): Dr Philip Hampton

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2024 The Author(s). Pyoderma gangrenosum (PG) is an ulcerative inflammatory disorder affecting the lower legs in 80% of patients. The use of biologic medications to treat PG is increasing, although there is a limited evidence base to guide treatment choices. In some health systems, such as the UK National Health Service, limitations are placed on biologic prescribing for PG, leading to wide variations in prescribing. A survey of mainly UK clinicians showed that prednisolone remains the first-line treatment for PG (90%, 34/38). Biologics have been used by 66% (25/38) of clinicians as second-line therapy, but 19% (7/38) have had prescribing requests declined. Further research is needed to determine optimal treatment strategies for PG.

Publication metadata

Author(s): Jenkins M, Watson N, McPhee M, Levell NJ, Arden-Jones M, Ormerod AD, Hampton PJ

Publication type: Article

Publication status: Published

Journal: Clinical and Experimental Dermatology

Year: 2024

Volume: 49

Issue: 10

Pages: 1213-1216

Print publication date: 01/10/2024

Online publication date: 25/04/2024

Acceptance date: 22/04/2024

ISSN (print): 0307-6938

ISSN (electronic): 1365-2230

Publisher: Oxford University Press

URL: https://doi.org/10.1093/ced/llae153

DOI: 10.1093/ced/llae153

PubMed id: 38661219

Altmetrics

Share